TNFSF13B and myasthenia gravis: Of note, a Phase 2 study evaluating the efficacy and safety of belimumab in generalized MG patients was conducted but did not meet the primary endpoint, suggesting that BAFF-only inhibition is insufficient to drive clinical responses (55).